Loading...
Randomized phase II/III clinical trial of elpamotide for patients with advanced pancreatic cancer: PEGASUS-PC Study
Gemcitabine is a key drug for the treatment of pancreatic cancer; however, with its limitation in clinical benefits, the development of another potent therapeutic is necessary. Vascular endothelial growth factor receptor 2 is an essential target for tumor angiogenesis, and we have conducted a phase...
Na minha lista:
| Udgivet i: | Cancer Sci |
|---|---|
| Main Authors: | , , , , , , , , , , , , , , , , , |
| Format: | Artigo |
| Sprog: | Inglês |
| Udgivet: |
John Wiley & Sons, Ltd
2015
|
| Fag: | |
| Online adgang: | https://ncbi.nlm.nih.gov/pmc/articles/PMC4520640/ https://ncbi.nlm.nih.gov/pubmed/25867139 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1111/cas.12674 |
| Tags: |
Tilføj Tag
Ingen Tags, Vær først til at tagge denne postø!
|